Mekonos closes $25M funding round for cell therapy platform

Mekonos closes funding of $25M in a series a round as it develops the future of cell therapies on a chip. The...

Superbugs Could Be the Next Pandemic: We Need a Global, Comprehensive Plan to Address Them Now!

COVID-19 is clearly a generation-defining public health crisis; one which could have a lasting impact on many facets of our lives for many years to come.

AstraZeneca partners with Imperial’s VaxEquity to bolster its self-amplifying RNA based drugs pipeline

AstraZeneca has inked a deal with VaxEquity, a firm producing experimental COVID-19 vaccine of U.K.’s Imperial College, to develop and market drugs...

Chinese Pharma Companies Pushing for Global Reach with focus on R&D

In targeted therapies, drugs are used to “target” cancerous cells without having an adverse impact on normal cells during cancer treatments. In...

Korean firm JW Pharma gets European Patent Office approval for gout treatment

A South Korean pharma company, JW Pharmaceuticals, has recently reported a grant of patent to its homegrown gout treatment, URC102, by European...

Coherus to move beyond biosimilars with a cancer immunotherapy drug

Coherus Biosciences, known for developing biosimilars, had decided to extend its objectives in February.  The company has now stepped into developing innovative...

China based Lynk Pharma raises $50M in series B funding round

The Chinese pharmaceutical R&D company, Lynk Pharmaceuticals Co. Ltd., has successfully raised $50 million in Series B funding round.

FDA rejects AstraZeneca and FibroGen’s roxadustat NDA for CKD related anemia

FibroGen and AstraZeneca new drug application (NDA) for roxadustat to treat anaemia associated with chronic kidney disease (CKD) has been rejected by...

Latest news

Patient-Centric Clinical Trials And The Role Of A Travel Concierge

Many people find booking plane tickets, arranging road transportation and overnight lodging overwhelming. Add into that mix...
- Advertisement -

China forces insulin price cuts resulting in pullback for global pharma players

Xinhua, a Chinese news channel, commented on the price cut on insulin which was brought on by...

Aussie pharma CSL in talks to buy Swiss firm Vifor Pharma for USD 7B

CSL, the Australian giant, is in talks to buy Vifor Pharma in a deal that is valued...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you

Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam

a clinical-stage biotechnology company developing product candidates for Alzheimer's disease, today announced

Daewoong Pharmaceutical and Evolus partner to enter European market

Daewoong Pharmaceutical is seeking to enter the European botulinum toxin market by strengthening its partnership with Evolus

In migraine drug battle, Eli Lilly to be sued by Teva after securing patents for Ajovy.

Teva Pharmaceuticals, the manufacturer of Ajovy, and Eli Lilly, the developer of Emgality, are embroiled in a patent battle over CGRP.
Nominations for Top Industry Leaders Awards are now open!